Sanofi looks cheap — but years of R&D setbacks, revolving-door CEOs, and heavy reliance on Dupixent explain the discount. Our independent take on why the real turnaround hinges on fixing internal R&D from the inside.
Markets are cooling on a year of AI-driven speculation as debt funding tightens. AlphaValue expects ...
As tensions in Hormuz and the Russia-Ukraine energy standoff raise the risk of a major military acci...
AlphaValue's Fundamental Strength Indicator reveals 24 "unsinkable" business mo...
Subscribe to our blog
A $330 share price, 40x earnings expected five years from now, and growth funded by SoftBank: wh...
European defence is no longer the cozy oligopoly it once was. Rising competition from AI-driven sta...